Back to today’s briefing

Story perspectives

Study Links GLP-1 Medications to Reduced Dementia Risk

1/21/2025

41 8

Summary

Veterans' Health Breakthrough

A groundbreaking study of over 2 million veterans reveals that GLP-1 receptor agonists, such as Ozempic and Wegovy, can dramatically lower the risks of dementia, Alzheimer’s, and substance use disorders. Yet, caution is warranted, as these medications may also lead to pancreatitis and kidney complications, underscoring the importance of vigilant patient oversight.

Summary

Dementia Risk Surge

Dementia cases in the U.S. are set to skyrocket, with projections estimating nearly 1 million cases annually by 2060. Alarmingly, 42% of Americans over 55 are at risk, particularly women, Black adults, and those with the APOE4 gene. The time for urgent prevention and early diagnosis is now.

1 of 2

Veterans' Health Breakthrough

A groundbreaking study of over 2 million veterans reveals that GLP-1 receptor agonists, such as Ozempic and Wegovy, can dramatically lower the risks of dementia, Alzheimer’s, and substance use disorders. Yet, caution is warranted, as these medications may also lead to pancreatitis and kidney complications, underscoring the importance of vigilant patient oversight.

1 / 2